Table 1.
Characteristics of SLE pregnancies overall and according to aspirin use
| Characteristic | All pregnant visits (n=475)* | Pregnant visits with aspirin (n=121) | Pregnant visits without aspirin (n=354) |
| Patient characteristic | |||
| Age, mean (SD) | 31.0 (4.9) | 30.5 (4.6) | 31.2 (5.0) |
| Ethnicity, n (%) | |||
| Asian | 66 (14) | 7/66 (11) | 59/66 (89) |
| Native North American | 3 (1) | 2/3 (67) | 1/3 (33) |
| Black | 88 (19) | 9/88 (10) | 79/88 (90) |
| Caucasian | 209 (44) | 71/209 (34) | 138/209 (66) |
| Hispanic | 62 (13) | 20/62 (32) | 42/62 (68) |
| Indian subcontinent | 25 (5) | 8/25 (32) | 17/25 (68) |
| Other | 22 (5) | 4/22 (18) | 18/22 (82) |
| Country, n (%) | |||
| Canada | 121 (25) | 27/121 (22) | 94/121 (78) |
| USA | 105 (22) | 20/105 (19) | 85/105 (81) |
| Mexico | 52 (11) | 19/52 (37) | 33/52 (63) |
| Europe | 146 (31) | 49/146 (34) | 97/146 (66) |
| South Korea | 51 (11) | 6/51 (12) | 45/51 (88) |
| Any postsecondary education, n (%) | 310/452 (69) | 69/310 (22) | 241/310 (78) |
| BMI, mean (SD) | 25.8 (5.9) | 26.3 (5.2) | 25.6 (6.1) |
| Obstetrical history | |||
| Parity, mean (SD) | 1.1 (1.0) | 1.1 (1.0) | 1.2 (1.0) |
| Nulliparous, n (%) | 134/461 (29) | 37/134 (28) | 97/134 (72) |
| Previous fetal loss <24 weeks, n (%) | 84/456 (18) | 22/84 (26) | 62/84 (74) |
| SLE characteristics | |||
| Disease duration (years), mean (SD) | 5.6 (3.3) | 5.6 (3.3) | 5.6 (3.3) |
| SLEDAI, mean (SD) | 3.3 (3.8) | 3.0 (3.6) | 3.4 (3.9) |
| SLICC damage score, mean (SD) | 0.5 (1.0) | 0.6 (1.0) | 0.5 (1.0) |
| Any positive aPL, n (%) | 34/104 (33) | 13/34 (38) | 21/34 (62) |
| LAC, n (%) | 19/104 (18) | 6/19 (32) | 13/19 (68) |
| ACL, n (%) | 12/104 (12) | 3/12 (25) | 9/12 (75) |
| GP1 IgG, n (%) | 18/104 (17) | 9/18 (50) | 9/18 (50) |
| Nephritis, n (%) | 53(11) | 11/53(21) | 42/53 (79) |
| Comorbidities | |||
| Any renal disease†, n (%) | 83 (17) | 17/83 (20) | 66/83 (80) |
| CKD (eGFR≤90 mL/min/1.73 m²), n (%) | 43/459 (9) | 6/43 (14) | 37/43 (86) |
| CKD stage ≤3 (eGFR≤60 mL/min/1.73 m²), n (%) | 11/459 (2) | 5/11 (45) | 6/11 (55) |
| Hypertension, n (%) | 79 (17) | 24/79 (30) | 55/79 (70) |
| Taking anticoagulation, n (%) | 28 (6) | 12/28 (43) | 15/28 (54) |
| Year of pregnancy visit | |||
| 2000– 2004, n (%) | 39 (8) | 11/39 (28) | 28 (72) |
| 2005– 2009, n (%) | 157 (33) | 46/157 (29) | 111/157 (71) |
| 2010– 2014, n (%) | 218 (46) | 52/218 (24) | 166/218 (76) |
| 2015– 2017, n (%) | 61 (13) | 12/61 (20) | 49/61 (80) |
*Denominator=475 unless otherwise stated.
†Includes chronic kidney disease, active nephritis and/or nephrotic syndrome within the last year.
ACL, anticardiolipin antibody; aPL, antiphospholipid antibody; BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GP1, anti-B2-glycoprotein-1; LAC, lupus anticoagulant; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics.